

MEMORANDUM

(1-1-81)

1981

Subject: Meeting on Metabolite Toxicology Reviews

To: Files 100-587, 100-597

Participants

Bill Bannum Tox Branch, HED

Jim Akerman FHB, RD

Gary Burin " "

Dick Mountfort " "

Larry Chittick " "

Jim Stow, " "

A meeting was held to discuss current status of the ^{toxicity} review of metabolite petitions. RD pointed out that some had been pending over a year and that ~~we~~ we needed a review.

Discussion was held on two areas.

(1) ADI: It was concluded that the proposed tolerance would have added 20-40% to the ADI (100-200% of the TMRC) and wouldn't have been a problem

except for this review of the IBT chronic rat study.

Our toxicologists

(2) IBT rat study: ~~They~~ have concluded the this study is supplemental but shows oncogenic effect in the liver at the high dose. Although previous reviews and ~~under~~ the Metabolite Standard indicated that this study showed no evidence of oncogenicity, this ^{conclusion} is incorrect. They said they could find no review for this study, only the evaluation

report indicating the study was supplemented
on the part, they did not review supplemented
IST studies. They ~~can not~~ ignore the results
and ~~had~~ ^{were} conducted a one-hit risk assessment
which indicated that ~~a~~ ^{risk is} in the middle
of the range (10^{-5} - 10^{-6}).

It was decided that today they would give
us their review, and once we received it
we would telephone Ciba-Geigy informing
them of the results of the review of the
risk study. They would be willing to meet
with the company. They would review the
data submitted last week (not reproduction, 12 week
interim report on the new chronic rat study)
to see if adverse effects were found in the
study, and they would conduct a
complete risk assessment in the next ~~one~~
to two ~~months~~ ^{months}. The decision would be
made on the proposed tolerance at this
time.